This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Break-Through Invention For Treating Cancer

Stock quotes in this article: GENE

ImmunAid Pty. Ltd. has been awarded a European patent for its pioneering work in the treatment of cancer, based on monitoring the immune cycle of each individual patient and then determining the optimal time to deliver treatment to that patient.

Dr. Svetomir Markovic, chair of the Melanoma Group at Mayo Clinic, Rochester, MN, says, “The discovery of the regulated immune response cycle in cancer patients is potentially of immense clinical significance with profound public health implications.”

Approximately $32 billion is spent globally each year on cancer drugs, yet the cancer mortality rate in the United States is more than 11,000 per week. An analysis of 63 clinical trials published since 2000 shows the average complete response rate--becoming cancer free--in late-stage patients across a wide range of cancers is 7 percent.

ImmunAid Pty. Ltd. is a private Australian biotechnology company, majority owned by Genetic Technologies Limited (ASX-GTG, NASDAQ-GENE). ImmunAid was founded a decade ago to explore the concept developed by inventor Martin Ashdown that the immune system switches itself “on and off” in a continuous, repeating cycle in patients with certain diseases, including auto-immune disease, and that treatment should be timed to support the body’s own efforts to fight off such disease. Subsequently, Ashdown expanded his concept to include cancer and several degenerative diseases.

Ashdown and the ImmunAid research team demonstrated that the immune system of cancer patients undergoes a repeating cycle, and that the administration of treatment at certain critical moments within that cycle can significantly improve the clinical outcome.

Dr. Mervyn Jacobson, ImmunAid chief executive officer, says. “Once we realized this immune cycle is real and measurable, we postulated that the administration of chemotherapy and other anti-cancer therapies should be timed to work with each individual patient’s immune system to attack the cancer. The results then spoke for themselves.”

Professor Brendon Coventry, a senior surgical consultant and practicing surgeon at Royal Adelaide Hospital, has conducted extensive clinical trials over several years in conjunction with ImmunAid. He says, “Treatments ‘randomly’ given without consideration to a patient’s immune cycle explains why some patients achieve a complete recovery and others do not.”

The Mayo Clinic currently is conducting an independently funded clinical trial to further assess the influence of timed delivery of conventional chemotherapy for patients with cancer, and several hospitals and universities in Australia are now conducting trials on cancer and also a number of other diseases, including multiple sclerosis and human immunodeficiency virus (HIV).

Dr. Markovic states, “I have been struck by the scientific community’s acknowledgement of the increasing validity of ImmunAid’s work. In Mayo’s ongoing experience, timed delivery of chemotherapy appears to offer added therapeutic benefit in the treatment of metastatic melanoma.”



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs